Limb-girdle Muscular Dystrophy
Disease Details
Family Health Simplified
- Description
- Limb-girdle muscular dystrophy is a group of genetic disorders characterized by progressive muscle weakness and wasting, primarily affecting the shoulder and hip muscles.
- Type
-
Limb-girdle muscular dystrophy (LGMD) encompasses a group of genetic disorders characterized by progressive muscle weakness and wasting, primarily affecting the hip and shoulder muscles. LGMD can follow different patterns of genetic transmission, including:
1. Autosomal recessive inheritance: This is the most common pattern for LGMD, where an affected individual inherits two copies of the defective gene, one from each parent.
2. Autosomal dominant inheritance: In this case, an affected individual inherits one copy of the defective gene from one parent, and this is sufficient to cause the disorder. - Signs And Symptoms
-
By definition, all limb girdle muscular dystrophies (LGMD) cause progressive proximal weakness, meaning weakness of the muscles on or close to the torso that worsens over time. Explicitly, LGMD preferentially affects muscles of the hip girdle, thigh, shoulder girdle, and/or upper arm. The muscle weakness is generally symmetric. Usually, the hip girdle is the first area to exhibit weakness, manifesting as difficulty walking, going up and/or down stairs, rising from a chair, bending at the waist, or squatting. Because of these difficulties, falling can occur frequently. Weakness of the shoulder girdle can make lifting objects, or even elevating the arms, difficult or impossible. Rate of progression varies between patients. Eventually, the abilities to run and walk can deteriorate. The disease commonly leads to dependence on a wheelchair within years of symptom onset, although some patients maintain mobility. Eventually the disease can affect other muscles such as the ones located in the face.
By definition, LGMDs primarily affect skeletal muscles, although cardiac muscle can be affected to a lesser degree in select subtypes, which can cause palpitations.
There can be significant variability in disease features and severity between LGMD subtypes, and even within any given LGMD subtype. Additional possible presentations include:
In most cases, pain is not present with LGMD, and mental function is not affected. LGMD can begin in childhood, adolescence, young adulthood or even later, the age of onset is usually between 10 and 30. Both genders are affected equally. When limb-girdle muscular dystrophy begins in childhood, the progression appears to be faster and the disease more disabling. When the disorder begins in adolescence or adulthood the disease is generally not as severe and progresses more slowly. There is no sensory neuropathy or autonomic or visceral dysfunction at presentation. - Prognosis
- In terms of the prognosis of limb–girdle muscular dystrophy in its mildest form, affected individuals have near-normal muscle strength and function. LGMD isn't typically a fatal disease, though it may eventually weaken the heart and respiratory muscles, leading to illness or death due to secondary disorders.
- Onset
- The onset of limb-girdle muscular dystrophy (LGMD) can vary widely depending on the specific subtype. Generally, the symptoms can appear anywhere from childhood to adulthood. Some forms present in early childhood, while others may not become apparent until late teenage years or even adulthood.
- Prevalence
- Limb-girdle muscular dystrophy (LGMD) encompasses a diverse group of genetic disorders, each subtype having its own specific prevalence. Collectively, LGMDs are relatively rare, with estimates suggesting a prevalence of approximately 1 in 14,500 to 1 in 123,000 individuals worldwide. The frequency can vary significantly based on geographic region and specific subtype.
- Epidemiology
- The minimum prevalence of limb–girdle muscular dystrophy, as a group, likely ranges from 2.27-10 per 100,000 (1:44,000 to 1:10,000). LGMD is the fourth most common muscular dystrophy, after the dystrophinopathies, myotonic dystrophies, and facioscapulohumeral muscular dystrophy. The prevalence of individual LGMDs, as studied in the United States, in descending order, are those due to mutation of 1) calpain, 2) dysferlin, 3) collagen VI, 4) sarcoglycans, 5) anoctamin 5, and 6) fukutin-related protein. In Euroasia CAPN3 mutations are the most common cause of LGMD, however in northern Europe mutations in FKRP are also very common. It is difficult to calculate the worldwide prevalence of even the most common LGMD types, due to the founder effect causing varying prevalence by region. The less common types are very rare, often only described is limited regions of the world.
- Intractability
- Limb-girdle muscular dystrophy (LGMD) is generally considered intractable because it currently has no cure. The disease is characterized by progressive muscle weakness and wasting, primarily affecting the shoulder and hip girdle muscles. Treatment focuses on managing symptoms, maintaining mobility, and improving quality of life through physical therapy, supportive devices, and, in some cases, medications.
- Disease Severity
- Limb-girdle muscular dystrophy (LGMD) varies greatly in severity. Some individuals experience only mild muscle weakness and can maintain mobility throughout their lives, while others may have severe weakness and lose the ability to walk at a young age. The progression rate and muscle groups affected can also differ significantly between subtypes of LGMD.
- Healthcare Professionals
- Disease Ontology ID - DOID:11724
- Pathophysiology
- Limb-Girdle Muscular Dystrophy (LGMD) is a group of genetic disorders characterized by progressive muscle weakness and atrophy, primarily affecting the muscles around the shoulders and hips. The pathophysiology of LGMD involves mutations in various genes responsible for producing proteins essential for muscle function and stability. These mutations lead to defective or insufficient proteins, resulting in muscle fiber damage, inflammation, and degeneration over time. The specific proteins and cellular pathways affected can vary depending on the type of LGMD, which is classified based on the particular gene mutation involved.
- Carrier Status
- Limb-Girdle Muscular Dystrophy (LGMD) is a group of genetic disorders affecting voluntary muscles, primarily those around the hips and shoulders. It can be inherited in both autosomal dominant and autosomal recessive patterns. Carrier status specifically refers to individuals who carry one copy of a recessive gene mutation for autosomal recessive LGMD. These carriers typically do not show symptoms of the disease but can pass the mutation to their offspring. If both parents are carriers, their child has a 25% chance of inheriting two faulty genes (one from each parent) and being affected by LGMD. For autosomal dominant LGMD, a single copy of the mutated gene can cause the disorder, so carrier status typically isn't applicable in the same way, as a single copy leads to disease expression.
- Mechanism
-
Limb-girdle muscular dystrophy (LGMD) is a group of inherited disorders characterized by progressive muscle weakness and wasting, primarily affecting the shoulder and pelvic girdles.
**Mechanism:**
The primary mechanism involves mutations in genes that encode proteins critical for muscle function. These mutations disrupt various cellular processes, leading to muscle fiber degeneration and weakness.
**Molecular Mechanisms:**
1. **Sarcolemmal Protein Defects:**
- Defects in proteins like dystrophin and sarcoglycans disrupt the stability and integrity of the muscle cell membrane (sarcolemma), causing muscle damage.
2. **Extracellular Matrix Proteins:**
- Mutations in genes encoding extracellular matrix proteins, such as collagen VI, impair muscle structure and function.
3. **Enzymatic Activity:**
- Defective enzymes, like calpain-3, impact proteolytic pathways essential for muscle maintenance and repair.
4. **Nuclear Envelope Proteins:**
- Abnormalities in proteins like lamin A/C affect nuclear integrity and muscle cell function.
5. **Transport Proteins:**
- Mutations in transport proteins, such as dysferlin, disrupt vesicle trafficking and membrane repair mechanisms.
These molecular defects collectively lead to progressive muscle weakness, primarily affecting proximal muscles. Different forms of LGMD result from specific gene mutations, leading to a heterogeneous group of disorders with variable severity and progression. - Treatment
-
There are few studies corroborating the effectiveness of exercise for limb–girdle muscular dystrophy. However studies have shown that exercise can, in fact, damage muscles permanently due to intense muscle contraction. Physical therapy may be required to maintain as much muscle strength and joint flexibility as possible. Calipers may be used to maintain mobility and quality of life. Careful attention to lung and heart health is required, corticosteroids in LGMD 2C-F individuals, shows some improvement. Additionally individuals can follow management that follows:
Occupational therapy
Respiratory therapy
Speech therapy
Neutralizing antibody to myostatin should not be pursuedThe sarcoglycanopathies could be possibly amenable to gene therapy. - Compassionate Use Treatment
-
Limb-girdle muscular dystrophy (LGMD) is a group of genetic disorders characterized by progressive muscle weakness, primarily affecting the hip and shoulder muscles. There are limited specific treatments available, but some options under compassionate use, off-label, or experimental treatments can be considered. These may include:
1. **Gene Therapy**: Investigational gene therapies aim to target specific mutations causing LGMD. Clinical trials are ongoing to evaluate the efficacy and safety of these therapies.
2. **Ataluren (PTC124)**: Initially developed for Duchenne muscular dystrophy, ataluren is being explored for off-label use in certain types of LGMD caused by specific genetic mutations that lead to premature stop codons.
3. **CRISPR-Cas9**: This gene-editing technology is being explored experimentally to correct genetic mutations causing LGMD. Early-stage research is ongoing.
4. **Myostatin Inhibitors**: These experimental therapies aim to block myostatin, a protein that inhibits muscle growth. By inhibiting myostatin, muscle strength and mass may be improved in LGMD patients. Clinical trials are investigating various myostatin inhibitors.
5. **Exon Skipping**: Similar to its application in Duchenne muscular dystrophy, exon skipping is being researched as a potential strategy to bypass faulty sections of the gene and restore more normal protein production in specific forms of LGMD.
6. **Stem Cell Therapy**: Experimental studies are evaluating the potential of stem cell treatments to regenerate muscle tissue and improve muscle function in LGMD patients.
7. **Corticosteroids**: While not a cure, corticosteroids are sometimes used off-label to manage symptoms and slow progression by reducing inflammation and muscle damage.
8. **Anti-inflammatory and Immunosuppressive Drugs**: These may be considered under compassionate use to manage symptoms if there is an inflammatory component to the disease.
Patients considering these options should consult with their healthcare provider to understand the potential benefits and risks, as well as eligibility for clinical trials or compassionate use programs. - Lifestyle Recommendations
-
For individuals with Limb-Girdle Muscular Dystrophy (LGMD), the following lifestyle recommendations can be helpful:
1. **Regular Exercise**: Engage in low-impact exercises, like swimming or stationary cycling, to maintain muscle strength and flexibility. Avoid high-intensity workouts that might cause muscle damage.
2. **Physical Therapy**: Regular sessions with a physical therapist can help maintain mobility and prevent contractures.
3. **Balanced Diet**: Eat a nutritious diet to maintain a healthy weight and support overall health. Avoid excessive weight gain which can put additional stress on weakened muscles.
4. **Assistive Devices**: Use braces, canes, or wheelchairs as necessary to aid in mobility and reduce the risk of falls.
5. **Breathing Exercises**: Practice respiratory exercises and use recommended devices to strengthen respiratory muscles, especially if the disease affects breathing.
6. **Heart Monitoring**: Regular cardiovascular check-ups are important as some forms of LGMD can affect heart muscles.
7. **Avoiding Fatigue**: Pacing activities and taking frequent rests can help manage fatigue and prevent muscle overuse.
8. **Home Modifications**: Make necessary adjustments at home (ramps, handrails, etc.) to ensure safety and ease of movement.
9. **Mental Health Support**: Engage with support groups and mental health professionals to cope with the emotional and psychological effects of living with LGMD. - Medication
-
Limb-girdle muscular dystrophy (LGMD) is a group of genetic disorders characterized by progressive muscle weakness, primarily affecting the shoulder and pelvic girdles. There is no cure for LGMD, and treatment primarily focuses on symptom management and maintaining quality of life.
Medications used may include:
1. **Corticosteroids**: These can help to slow muscle degeneration and improve strength in some subtypes.
2. **ACE Inhibitors and Beta-Blockers**: These may be used if there is involvement of the heart to manage cardiomyopathy.
3. **Pain Management**: Analgesics or anti-inflammatory drugs may be prescribed to manage muscle pain or discomfort.
Treatment plans are often individualized, and ongoing medical care typically involves a multidisciplinary team. - Repurposable Drugs
-
For limb-girdle muscular dystrophy (LGMD), several existing drugs are being investigated for their potential repurposing to alleviate symptoms or slow disease progression. These include:
1. **Corticosteroids**: Commonly used in other muscular dystrophies, they may help reduce inflammation and muscle damage.
2. **Tamoxifen**: Primarily a breast cancer drug, it has shown promise in preclinical models of muscular dystrophy by helping to preserve muscle function.
3. **Metformin**: A diabetes medication, also being studied for its possible benefits in muscle repair and growth due to its anti-inflammatory and metabolic effects.
4. **Ataluren**: Currently used for other types of muscular dystrophy, it helps with nonsense mutation suppression, potentially useful in specific genetic mutations causing LGMD.
Research is ongoing, and the efficacy of these drugs for LGMD patients is still being thoroughly evaluated. - Metabolites
-
Limb-girdle muscular dystrophy (LGMD) does not have a specific set of metabolites uniquely associated with it, but metabolic studies can help reveal abnormalities in muscle tissues. Common techniques include muscle biopsy and imaging to analyze metabolic pathways and potential disruptions due to the disease.
In the context of LGMD, changes in metabolites like creatine kinase (CK) are often observed. Elevated CK levels in the blood can indicate muscle damage, which is a hallmark of muscular dystrophies, including LGMD. Additionally, lactate and pyruvate levels might be studied to understand mitochondrial function and energy metabolism in affected individuals.
Research into detailed metabolomic profiles of LGMD is ongoing, aiming to better understand disease mechanisms and potential biomarkers, but no definitive set of metabolites is currently established as a standard for diagnosis or monitoring.
Nanotechnology has potential therapeutic and diagnostic applications for LGMD. This includes targeted drug delivery systems, nanocarriers encapsulating therapeutic agents to improve tissue localization, and nanodiagnostics for improved biomarker detection and disease monitoring. However, most of these applications are still under research and not yet in widespread clinical use.
To summarize, while specific metabolite profiles for LGMD are not fully established, elevated CK and studies on energy metabolism are common. Nanotechnology holds promise for future advancements in diagnosis and treatment. - Nutraceuticals
-
Nutraceuticals generally refer to products derived from food sources that provide extra health benefits in addition to their basic nutritional value. For limb-girdle muscular dystrophy (LGMD), there is limited scientific evidence supporting the effectiveness of specific nutraceuticals in treating or managing the condition. However, certain supplements might help manage symptoms and improve overall health:
1. **Antioxidants**: Supplements such as vitamin E, vitamin C, and coenzyme Q10 might help reduce oxidative stress in muscle tissues.
2. **Omega-3 Fatty Acids**: Found in fish oil, omega-3 fatty acids could help reduce inflammation.
3. **Creatine**: This compound may help improve muscle strength and endurance in some individuals.
It's important to consult with a healthcare professional before starting any nutraceutical regimen, as they can provide advice tailored to the individual’s specific condition and needs. - Peptides
-
Limb-girdle muscular dystrophy (LGMD) encompasses a group of genetic disorders that cause progressive muscle weakness, primarily affecting the shoulder and hip areas.
**Peptides**: In the context of LGMD, research into peptide therapies is ongoing but not yet a standard treatment. Peptides may be used in experimental therapies to modulate gene expression or protein function to address the underlying genetic defects causing the disease.
**Nanotechnology**: Nanotechnology is also being explored as a potential therapeutic approach for LGMD. This includes the use of nanoparticles for targeted drug delivery to muscle cells or gene therapy. The aim is to improve the efficacy and reduce the side effects of treatments by targeting the delivery more precisely.
Both approaches are still primarily in the research phase and are not yet widely available as standard treatments for individuals with LGMD.